Beacon Biosignals has upsized its Series B financing to $97 million, bringing cumulative funding to over $132 million, according to the company. The extension adds new investors JSL Health, Palo Santo VC, Kicker Ventures and Samsung Next to a syndicate that previously led an $86 million Series B, including Innoviva, GV, S32, Catalio Capital Management, General Catalyst, Logos Capital, Casdin Capital and Indicator Ventures.
The company claims the new capital will accelerate development of at-home EEG and advanced analytics for diagnostics, clinical trials and precision medicine.
Beacon combines FDA-cleared wearable EEG technology with AI analytics to capture and analyze real-world neural data, according to the company. Funds will support clinical expansion and commercialization efforts.
